185 related articles for article (PubMed ID: 8995232)
1. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease.
Riddell DR; Graham A; Owen JS
J Biol Chem; 1997 Jan; 272(1):89-95. PubMed ID: 8995232
[TBL] [Abstract][Full Text] [Related]
2. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets.
Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Trovati M
Eur J Clin Invest; 2001 May; 31(5):452-61. PubMed ID: 11380598
[TBL] [Abstract][Full Text] [Related]
3. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase.
Moro MA; Russel RJ; Cellek S; Lizasoain I; Su Y; Darley-Usmar VM; Radomski MW; Moncada S
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1480-5. PubMed ID: 8643658
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion.
Riddell DR; Owen JS
Thromb Res; 1996 Mar; 81(5):597-606. PubMed ID: 9054055
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
6. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.
Radomski MW; Palmer RM; Moncada S
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5193-7. PubMed ID: 1695013
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion.
Riddell DR; Owen JS
Thromb Res; 1995 Dec; 80(6):499-508. PubMed ID: 8610278
[TBL] [Abstract][Full Text] [Related]
8. Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect.
Trovati M; Massucco P; Mattiello L; Mularoni E; Cavalot F; Anfossi G
Diabetes; 1994 Aug; 43(8):1015-9. PubMed ID: 7518780
[TBL] [Abstract][Full Text] [Related]
9. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
Gordge MP; Hothersall JS; Noronha-Dutra AA
Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
[TBL] [Abstract][Full Text] [Related]
11. Ketamine activates the L-arginine/Nitric oxide/cyclic guanosine monophosphate pathway to induce peripheral antinociception in rats.
Romero TR; Galdino GS; Silva GC; Resende LC; Perez AC; Côrtes SF; Duarte ID
Anesth Analg; 2011 Nov; 113(5):1254-9. PubMed ID: 21788321
[TBL] [Abstract][Full Text] [Related]
12. The effect of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide.
Onoue H; Katusic ZS
Brain Res; 1998 Feb; 785(1):107-13. PubMed ID: 9526059
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide inhibits platelet adhesion to collagen through cGMP-dependent and independent mechanisms: the potential role for S-nitrosylation.
Irwin C; Roberts W; Naseem KM
Platelets; 2009 Nov; 20(7):478-86. PubMed ID: 19852686
[TBL] [Abstract][Full Text] [Related]
14. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
15. Whole brain spheroid cultures as a model to study the development of nitric oxide synthase-guanylate cyclase signal transduction.
Teunissen CE; Steinbusch HW; Markerink-van Ittersum M ; De Bruijn C ; Axer H; De Vente J
Brain Res Dev Brain Res; 2000 Dec; 125(1-2):99-115. PubMed ID: 11154766
[TBL] [Abstract][Full Text] [Related]
16. Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect.
Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Balbo A; Trovati M
Thromb Res; 2002 Jan; 105(1):71-8. PubMed ID: 11864710
[TBL] [Abstract][Full Text] [Related]
17. The role of inhibition of nitric oxide synthesis in the aggregation of platelets due to the stimulated production of thromboxane A2.
Banerjee D; Mazumder S; Sinha AK
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):585-91. PubMed ID: 25083729
[TBL] [Abstract][Full Text] [Related]
18. Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.
Ferreira MA; do Nascimento NR; de Sousa CM; Pessoa OD; de Lemos TL; Ventura JS; Schattner M; Chudzinski-Tavassi AM
Br J Pharmacol; 2008 Jul; 154(6):1216-24. PubMed ID: 18516074
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro.
Bode-Böger SM; Böger RH; Galland A; Frölich JC
Naunyn Schmiedebergs Arch Pharmacol; 1998 Feb; 357(2):143-50. PubMed ID: 9521487
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
